Steve Lee, CEODespite significant advancements in 21st-century medicine, respiratory illnesses such as COVID-19, COPD, pneumonia, and pulmonary embolism continue to be a major burden on healthcare worldwide. In the U.S. alone, respiratory diseases account for the top three causes of death for hospitalized patients. Among the factors contributing to this challenge is that the tools commonly used to assess and treat respiratory ailments often only provide a small piece of the information needed to make the correct medical decisions, leading to a series of invasive, time-consuming tests.
MediPines, a market leader in non-invasive respiratory assessment technology, is advancing respiratory medicine by offering a physiologybased respiratory device, the AGM100, that enhances clinical effectiveness by simultaneously providing multiple sources of relevant clinical information at the bedside.
This FDA-cleared device takes an innovative non-invasive approach to respiratory assessment. By taking gas sampled from a patient breathing at rest, clinicians obtain multiple parameters simultaneously, enabling a more immediate clinical decision. With just a breath sample the AGM100 provides measurements including blood oxygenation (PaO2), ventilation (PCO2), and pulmonary gas exchange efficiency, also known as Oxygen Deficit. No other device directly addresses the lungs’ pulmonary gas exchange in real time at the bedside.
The AGM100 has been highlighted by the World Health Organization (WHO) as an innovative and commercially available health technology for global priority diseases. Unlike traditional methods, this device doesn’t rely on effort from the patient. Instead, it aligns closely with the natural functioning of human physiology, as gas exchange represents the goal of the respiratory system.
“As we provide a complete assessment of gas exchange efficiency, clinicians can rapidly determine the source and severity of the respiratory impairment to help guide the appropriate treatment,” said Steve Lee, MediPines’ founder, and co-inventor of AGM100.
Although the device was designed for broad adoption across the continuum of patient care, recent studies have revealed that in an ER setting, this information can efficiently facilitate patient triage, something that was missing during the onset of the COVID-19 pandemic.
MediPines’ solution is instrumental in mitigating the supply and demand mismatch in healthcare. It offers a considerable advantage to healthcare providers by delivering more than 10X improvement in cost and time efficiency compared to current modalities. This enables clinicians to provide controlled care with fewer resources, ultimately improving patient outcomes and reducing the burden on healthcare systems.
MediPines has obtained regulatory approval in the US, Canada, and a growing list of countries worldwide. The AGM100 is manufactured in California in a MDSAP/ISO13485 certified facility, the globally harmonized quality standard for manufacturing, sales, and support for medical device companies.
As we provide a complete assessment of gas exchange efficiency, clinicians can rapidly determine the source and severity of the respiratory impairment to help guide the appropriate treatment
MediPines’ innovative technology is built on decades of well-established respiratory physiology research. This technology has undergone extensive testing in various clinical settings and patient populations, including various disease states, severity, altitudes, and other physiologically stressed environments.
MediPines holds the potential to significantly impact patient care, drive provider efficiency, and lower overall healthcare system costs consistent with its founding mission of advancing respiratory medicine.
